论文部分内容阅读
目的:观察普米克令舒氧驱动雾化吸入治疗婴幼儿喘憋性肺炎的疗效。方法:将108例婴幼儿喘憋性肺炎患儿随机分为两组,两组均采用综合治疗,观察组加入普米克令舒氧驱动雾化吸入,对治疗前后症状、体征持续时间、治疗效果进行比较。结果:观察组在治愈率、缓解喘憋症状,缩短哮鸣音及咳嗽持续时间等方面均明显优于对照组(P<0.01)。结论:普米克令舒氧驱动雾化吸入治疗婴幼儿喘憋性肺炎有明显的优越性,疗效确切,方便、安全,可作为喘憋性肺炎的主要药物。
Objective: To observe the curative effect of Pulmicort respiration-assisted aerosol inhalation on infantile asthmatic pneumonia. Methods: A total of 108 infants and young children with asthmatic pneumonia were randomly divided into two groups. The two groups were treated with combination therapy. Pulmicort was added to the observation group to induce aerosol inhalation. The symptoms, the duration of the symptoms, the treatment effect Compare. Results: The observation group was significantly better than the control group (P <0.01) in terms of cure rate, relieving wheezing symptoms, shortening wheezing and cough duration. Conclusions: Pulmicort respiration oxygen inhalation therapy for infantile asthmatic pneumonia has obvious advantages, exact curative effect, convenience and safety, and can be used as the main drug for asthmatic pneumonia.